These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 1108625)
1. The benefit-to-risk ratio. Stamler J; Dipalma JR Am Fam Physician; 1976 Feb; 13(2):130-2. PubMed ID: 1108625 [No Abstract] [Full Text] [Related]
2. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ; Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292 [TBL] [Abstract][Full Text] [Related]
3. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ; J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046 [TBL] [Abstract][Full Text] [Related]
4. Lipid-lowering therapy after myocardial infarction: is it worth it? Warnica JW CMAJ; 1997 Apr; 156(7):1005-7. PubMed ID: 9099170 [No Abstract] [Full Text] [Related]
5. [Critical evaluation of indications for lipid reduction. Cholesterol value updated--risk counts (interview by Dr. Kirsten Westphal)]. Motz W MMW Fortschr Med; 2003 Oct; 145(41):48. PubMed ID: 14655487 [No Abstract] [Full Text] [Related]
6. Modern drug treatment--No. 8. Drugs and the prevention of death from myocardial infarction. Graham IM Ir Med J; 1982 Aug; 75(8):291-6. PubMed ID: 6127329 [No Abstract] [Full Text] [Related]
7. [Aftercare of heart infarct patients to reduce the risk of a subsequent infarction]. Offerhaus L Ned Tijdschr Geneeskd; 1983 Apr; 127(16):673-9. PubMed ID: 6134240 [No Abstract] [Full Text] [Related]
8. Treatable risk factors--hypercholesterolemia, smoking, and hypertension--after myocardial infarction: implications of the coronary drug project data for clinical management. Coronary Drug Project Research Group. Prim Care; 1980 Mar; 7(1):175-9. PubMed ID: 6992178 [TBL] [Abstract][Full Text] [Related]
9. [For prevention of cardiovascular diseases: statins in old age?]. MMW Fortschr Med; 2006 Sep; 148(38):16. PubMed ID: 17036955 [No Abstract] [Full Text] [Related]
10. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial. Goldenberg I; Boyko V; Tennenbaum A; Tanne D; Behar S; Guetta V Arch Intern Med; 2009 Mar; 169(5):508-14. PubMed ID: 19273782 [TBL] [Abstract][Full Text] [Related]
11. Trials and tribulations. Packard CJ Int J Clin Pract Suppl; 2002 Oct; (132):3-10. PubMed ID: 12425357 [No Abstract] [Full Text] [Related]
12. Prevention of myocardial reinfarction. Recommendations based on results of drug trials. Flaker GC; Singh VN Postgrad Med; 1993 Nov; 94(6):94-8, 102-4. PubMed ID: 7901845 [TBL] [Abstract][Full Text] [Related]
13. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Onuigbo MA Arch Intern Med; 2009 Oct; 169(19):1810; author reply 1810-1. PubMed ID: 19858442 [No Abstract] [Full Text] [Related]
14. [Secondary prevention after myocardial infarction]. Czuriga I Orv Hetil; 2002 Sep; 143(37):2117-28. PubMed ID: 12434627 [TBL] [Abstract][Full Text] [Related]
15. Secondary prevention of myocardial infarction with drugs. Klimt CR; Forman SA Isr J Med Sci; 1983 May; 19(5):460-70. PubMed ID: 6134697 [TBL] [Abstract][Full Text] [Related]